Please login to the form below

Not currently logged in
Email:
Password:

lumacaftor

This page shows the latest lumacaftor news and features for those working in and with pharma, biotech and healthcare.

Vertex gains EU approval for earlier Orkambi use

Vertex gains EU approval for earlier Orkambi use

Orkambi is a combination of lumacaftor and ivacaftor, which together targets the lack of CFTR proteins in CF patients.

Latest news

More from news
Approximately 4 fully matching, plus 19 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics